Masami Tamura

Masami Tamura is President and CEO of the CoreMed Corporation in Osaka, Japan

  • AdobeStock_418251752

    Can the Japanese phase I study be waived?


    New guidance: ‘Basic principles for conducting phase I studies in Japanese prior to initiating multi-regional clinical trials including Japan for drugs in which early clinical development is preceding outside Japan,’ issued in December 2023